Listing of Claims:

Following is a complete listing of the claims pending in the application:

1. (Currently amended) A method of increasing IL-10/IFNγ ratio in subjects suffering from multiple sclerosis, comprising

orally administering interferon-tau to the subject at a daily dosage of greater than about ~~5×10^8~~ 1×10^9 Units to produce an initial measurable increase in the subject's blood IL-10 level, relative to the blood IL-10 level in the subject in the absence of interferon-tau administration, with (i) no substantial change in the subject's blood IFNγ level relative to the IFNγ level in the absence of interferon-tau administration or (ii) a decrease in the subject's blood IFNγ level relative to the IFNγ level in the absence of interferon-tau administration, and

continuing to orally administer interferon-tau to the subject on a regular basis of at least several times per week, independent of changes in the subject's blood IL-10 level, until a desired clinical endpoint is achieved,

wherein the interferon-tau has at least 90% sequence homology to the polypeptide of SEQ ID NO: 2.

2. (Original) The method of claim 1, wherein said administering comprises administering an interferon-tau selected from ovine interferon-tau and bovine interferon-tau.

3. (Original) The method of claim 2, wherein said administering comprises administering ovine interferon-tau having a sequence identified as SEQ ID NO:2 or SEQ ID NO:3.

4. (Original) The method of claim 1, wherein said oral administration is to the intestinal tract of the subject.

5. (Previously presented) The method of claim 1, wherein said continuing to administer continues during the period of the subject's symptoms and the desired clinical endpoint is a reduction in symptoms associated with multiple sclerosis.

6-13. (Canceled)

14. (Original) The method of claim 1, further comprising administering a second therapeutic agent to the subject.

15. (Canceled)